Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s First Biotech Refinancing Deals in 2022 To Raise $712m

Executive Summary

Junshi and Chipscreen expect to raise a combined $711.9m in a private stock placement and issuance of convertible bonds to fund facilities construction and R&D.

You may also be interested in...



Three Chinese Biotechs Ride Market Recovery To Raise Funds

InventisBio and Akeso seek to gross a combined $384.3m in an initial public share sale in Shanghai and a private placement in Hong Kong respectively, while Chipscreen completed raising $74.4m by selling convertible bonds in Shanghai.

Chinese ADC Developers Catch Up with Global Players In Advancing Key Payloads

Chinese pharma firms led by Kelun are moving fast to develop the next-generation of cytotoxic "warheads," a key component of antibody-drug conjugates, disclosed company executives at conference in Suzhou.

China Grants First mRNA COVID Vaccine Approval To Homegrown Latecomer

CSPC Pharmaceutical's SYS6006 has gained an emergency use authorization in China less than one year after entering clinical trials, becoming the first mRNA vaccine for COVID-19 to be approved in the country.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel